PUBLIC COMPANY
save$CPRXCATALYST PHARMACEUTICALS, INC.
$CPRX31.490.00%Coral Gables, FL, USupdated 21d ago
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
community read0 votes
pipeline
2
marketed
2
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- —Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
- —Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
- phase3Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
- phase3Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
- phase2Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
🐶 Hiring Signal
News
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 14d ago
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BThe Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.stat · 3mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that